Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,013.59 +3.05 (+0.30%)
Streaming Delayed Price Updated: 9:56 AM EDT, Jun 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
37 38 Next >
Regeneron-Sanofi's Dupixent Significantly Improved Signs, Symptoms In Chronic Itchy Skin Disease
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) have presented  
Via Benzinga
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
Via Investor's Business Daily
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher. 
Via Investor's Business Daily
How do Biotechnology Funds and ETFs Perform Over Five Years?
Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV. 
Via Talk Markets
Regeneron Pharmaceuticals Inc. Climbs To Annual-High Share Price
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Shares of Regeneron Pharmaceuticals Inc... 
Via Benzinga
Regeneron Pharmaceuticals Inc. (REGN) Climbs to Annual-High Share Price
Via Investor Brand Network
Regeneron Pharmaceuticals Inc. (REGN) Climbs to Annual-High Share Price
Via Investor Brand Network
Matinas BioPharma Updates — Q4 2021 Earnings And Conference Call Recap
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Fed Rate Hike Rallies Stocks
The Federal Reserve led by Jerome Powell hiked interest rates for the first time in three years causing stocks to rally. 
Via Talk Markets
Best Biotech Stocks To Buy In 2022
Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and... 
Via Talk Markets
J.B. Hunt, Costco Lead Five Stocks Nearing Buy Points
J.B. Hunt and Costco are holding up near buy points in a tough market. 
Via Investor's Business Daily
Markets Fall Again As Russia-Ukraine War Erodes Investor Sentiment
U.S. Indices finished lower Friday amid continued uncertainty from the Russia-Ukraine conflict. The Nasdaq composite finished lower by 2.18% to 12,843; The Invesco QQQ Trust... 
Via Benzinga
Upcoming Stock Splits 2022: 20 Companies That Could Follow Amazon’s Lead
We're taking a gander at more companies that could follow Amazon's (AMZN) lead with potential upcoming stock splits in 2022. 
Via InvestorPlace
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116... 
Via Benzinga
WHO Conditionally Recommends Merck's COVID-19 Antiviral Pill For High-Risk Patients
A World Health Organization (WHO) panel has backed the use of Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral pill for high-risk patients. The expert... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
Intellia Shares Updated Data On Gene Editing Durability In Rare Disease
Eight months after delivering promising biomarker data from one of the first CRISPR trials, Intellia Therapeutics Inc (NASDAQ: NTLA) presented additional data... 
Via Benzinga
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
Via Investor's Business Daily
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended... 
Via Benzinga
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature. 
Via InvestorPlace
7 Low Volatility Stocks to Buy Right Now for Steady Returns
A great way to find low volatility stocks is to look for a beta that's less than 1.0. Here are seven to buy as market turbulence increases. 
Via InvestorPlace
KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?
Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session. 
Via InvestorPlace
S&P 500 Slips Further into Correction Territory as Stocks Give Up Gains
Stocks have pulled back from this morning's gains, amid the ongoing Russia-Ukraine border crisis, with all three benchmarks looking to extend their losing streaks. 
Via Talk Markets
Kodiak Stock Pummeled After Attempt To Improve On Regeneron's Blockbuster Backfired
Kodiak hoped a less frequent dosing plan would benefit patients with an eye disease. 
Via Investor's Business Daily
Why Kodiak Sciences Shares Are Plunging Today
Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-... 
Via Benzinga
Is Moderna the Next Gilead or the Next Regeneron?
MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed. 
Via InvestorPlace
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
37 38 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.